SCHEMBL25827075

SCHEMBL25827075

CCCCOCCOCCOCCOCCN1CCC(NCC)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GNAI3 P08754 6/20 0.43
GNAO1 P09471 6/20 0.43
GNAI1 P63096 6/20 0.43
HRH3 Q9Y5N1 5/20 0.41
CYP2C9 P11712 1/20 0.41
EPHX1 P07099 1/20 0.37
EPHX2 P34913 1/20 0.37
LTA4H P09960 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP1A2 P05177 1/20 0.36
CHRM2 P08172 1/20 0.36
CHRM1 P11229 1/20 0.36
HTR2A P28223 1/20 0.36
MAPK1 P28482 1/20 0.36
SCN1A P35498 1/20 0.36
HTR2B P41595 1/20 0.36
KCNH2 Q12809 1/20 0.36
SCN2A Q99250 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
SCN3A Q9NY46 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22790840 0.85 GNAI3 (0.44) GNAI3GNAO1GNAI1HRH3CYP2C9
SCHEMBL21107024 0.85 GNAI3 (0.34) GNAI3GNAO1GNAI1HRH3CYP2C9
SCHEMBL25699031 0.85 SLC6A2 (0.34) GNAI3GNAO1GNAI1HRH3CYP2C9
SCHEMBL26018288 0.85 GNAI3 (0.34) GNAI3GNAO1GNAI1HRH3CYP2C9
SCHEMBL25477755 0.84 PRMT6 (0.37) GNAI3GNAO1GNAI1HRH3CYP2C9
SCHEMBL25592083 0.84 GNAI3 (0.43) GNAI3GNAO1GNAI1HRH3CYP2C9
SCHEMBL25110079 0.83 GNAI3 (0.35) GNAI3GNAO1GNAI1HRH3CYP2C9
SCHEMBL25882001 0.83 PRMT6 (0.38) GNAI3GNAO1GNAI1HRH3CYP2C9
SCHEMBL22794388 0.81 GNAI3 (0.41) GNAI3GNAO1GNAI1HRH3CYP2C9
SCHEMBL25477738 0.81 GNAI3 (0.41) GNAI3GNAO1GNAI1HRH3CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 US disclosed
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-28 US disclosed
US-11746120-B2 Stat degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-09-05 US disclosed
US-20230219945-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11746120-B2 Stat degraders and uses thereof STAT4, STAT1, STAT3 GNAI3 3637/4885GNAO1 4203/4885GNAI1 3618/4885
US-20230219945-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 GNAI3 1664/4885GNAO1 2977/4885GNAI1 1458/4885
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 GNAI3 1664/4885GNAO1 2977/4885GNAI1 1458/4885
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 GNAI3 1664/4885GNAO1 2977/4885GNAI1 1458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.